hero image

Biogen to Present at the Evercore ISI 2nd Annual HealthCONx Conference

November 21, 2019 News Release

Cambridge, MA, - - Biogen Inc.  (Nasdaq: BIIB) announced today that it will present at the Evercore ISI 2nd Annual HealthCONx Conference. The webcast will be live on Tuesday, December 3, at 11:45a.m. ET, with Anirvan Ghosh, Ph.D., Senior Vice President and Head of Research and Early Development at Biogen. To access the live webcast, please visit Biogen’s Investors section at www.investors.biogen.com.  An archived version of the webcast will be available following the presentation.

About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics, and is focused on advancing research programs in multiple sclerosis and neuroimmunology, neuromuscular disorders, movement disorders, Alzheimer’s disease and dementia, ophthalmology, immunology, neurocognitive disorders, acute neurology, and pain.

We routinely post information that may be important to investors on our website at 
www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook, YouTube.
 
Contact:
Karen Jewell
Investor Relations
Biogen
781-464-2442

thumb
March 4, 2024
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting

New data advances understanding of new approaches to treating Alzheimer’s disease Research on disease progression could help inform future clinical trials CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced it will present new data from its Alzheimer’s disease

thumb
February 26, 2024
Biogen to Participate in the TD Cowen 44th Annual Health Care Conference

Cambridge, MA, - -  Biogen Inc. (Nasdaq: BIIB) announced today that Michael McDonnell, Chief Financial Officer, Priya Singhal, M.D., M.P.H., Head of Development, and Alisha Alaimo, Head of North America, will participate in a fireside chat during the TD Cowen 44th Annual Health Care Conference.